Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 203

1.

Return of ovulation following a single injection of depo-medroxyprogesterone acetate: a pharmacokinetic and pharmacodynamic study.

Lan PT, Aedo AR, Landgren BM, Johannisson E, Diczfalusy E.

Contraception. 1984 Jan;29(1):1-18.

PMID:
6234145
3.

Pharmacokinetic and pharmacodynamic investigations with monthly injectable contraceptive preparations.

Aedo AR, Landgren BM, Johannisson E, Diczfalusy E.

Contraception. 1985 May;31(5):453-69.

PMID:
4028723
4.

Ovarian function following a single administration of depo-medroxyprogesterone acetate (DMPA) at different doses.

Bassol S, Garza-Flores J, Cravioto MC, Diaz-Sanchez V, Fotherby K, Lichtenberg R, Perez-Palacios G.

Fertil Steril. 1984 Aug;42(2):216-22.

PMID:
6235131
5.

Effects of a sequential regimen of mifepristone-medroxyprogesterone acetate on ovarian function, endometrial development and hormonal parameters.

Croxatto HB, Massai MR, Salvatierra AM, Fuentealba B, Croxatto HD, Lähteenmäki P.

Contraception. 1996 Aug;54(2):79-86.

PMID:
8842583
7.

Pituitary, ovarian and endometrial effects of graded doses of medroxyprogesterone acetate administered on cycle days 7 to 10.

Zalányi S Jr, Aedo AR, Johannisson E, Landgren BM, Diczfalusy E.

Contraception. 1986 Jun;33(6):567-78.

PMID:
2945699
8.

Pharmacokinetics of depot medroxyprogesterone acetate contraception.

Mishell DR Jr.

J Reprod Med. 1996 May;41(5 Suppl):381-90. Review.

PMID:
8725700
10.
12.

Effect of depo-medroxyprogesterone acetate on serum progesterone levels when administered on various cycle days.

Siriwongse T, Snidvongs W, Tantayaporn P, Leepipatpaiboon S.

Contraception. 1982 Nov;26(5):487-93.

PMID:
6218964
13.

Serum norethindrone (NET) concentrations following intramuscular NET enanthate injection. Effect upon serum LH, FSH, estradiol and progesterone.

Goebelsmann U, Stanczyk FZ, Brenner PF, Goebelsmann AE, Gentzschein EK, Mishell DR Jr.

Contraception. 1979 Mar;19(3):283-313.

PMID:
572279
14.

Follicular development and ovulation in extremely obese women receiving depo-medroxyprogesterone acetate subcutaneously.

Segall-Gutierrez P, Taylor D, Liu X, Stanzcyk F, Azen S, Mishell DR Jr.

Contraception. 2010 Jun;81(6):487-95. doi: 10.1016/j.contraception.2010.01.021. Epub 2010 Mar 9.

PMID:
20472115
15.
16.

Pituitary, ovarian and endometrial effects of progesterone released prematurely during the proliferative phase.

Shumin X, Johannisson E, Landgren BM, Diczfalusy E.

Contraception. 1983 Feb;27(2):177-93.

PMID:
6851555
18.

Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA.

Ortiz A, Hirol M, Stanczyk FZ, Goebelsmann U, Mishell DR.

J Clin Endocrinol Metab. 1977 Jan;44(1):32-8.

PMID:
833262
19.
20.

Endocrine, seminal and peripheral effects of depot medroxyprogesterone acetate and testosterone enanthate in men.

Hedman M, Gottlieb C, Svanborg K, Bygdeman M, de la Torre B.

Int J Androl. 1988 Aug;11(4):265-76.

PMID:
2971625
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk